Pharmacokinetics and Safety Assessment of VX-121/Tezacaftor/Deutivacaftor in Participants With Moderate Hepatic Impairment

Key Inclusion Criteria: * Cohort 1: Participants with Moderate Hepatic Impairment * Participants will satisfy the criteria for moderate hepatic impairment defined as a Child-Pugh total score of 7 to 9 points at the screening visit * Participants will have chronic (≥6 months) documented liver disease * Cohort 2: Matched Healthy Participants * Participants will be matched during screening to participants with hepatic impairment for cigarette smoking habit, age, sex, and weight Key Exclusion Criteria: * Cohort 1: Participants with Moderate Hepatic Impairment * History of febrile illness or other acute illness * History of solid organ or bone marrow transplantation * History or presence of severe hepatic encephalopathy (Grade \>2) * Any condition possibly affecting drug absorption * Severe portal hypertension * Significant renal dysfunction (creatinine clearance \<50 milliliter per minute \[mL/min\] ) estimated according to the method of Cockcroft and Gault at the screening Visit or Day-1 * Cohort 2: Matched Healthy Participants * History of febrile illness or other acute illness * Any condition possibly affecting drug absorption Other protocol defined Inclusion/Exclusion criteria may apply.